1. Home
  2. JQC vs DAWN Comparison

JQC vs DAWN Comparison

Compare JQC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$5.01

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Logo Day One Biopharmaceuticals Inc.

DAWN

Day One Biopharmaceuticals Inc.

HOLD

Current Price

$8.28

Market Cap

624.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
DAWN
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
624.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JQC
DAWN
Price
$5.01
$8.28
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$26.56
AVG Volume (30 Days)
714.6K
2.6M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
11.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$133,672,000.00
Revenue This Year
N/A
$15.51
Revenue Next Year
N/A
$49.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.11
52 Week Low
$4.82
$5.64
52 Week High
$5.65
$13.53

Technical Indicators

Market Signals
Indicator
JQC
DAWN
Relative Strength Index (RSI) 41.13 47.22
Support Level $5.00 $7.90
Resistance Level $5.08 $8.67
Average True Range (ATR) 0.04 0.50
MACD 0.00 -0.09
Stochastic Oscillator 25.00 20.38

Price Performance

Historical Comparison
JQC
DAWN

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Share on Social Networks: